Full Text View
Tabular View
No Study Results Posted
Related Studies
flt3L With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma or Renal Cell Cancer
This study has been completed.
Study NCT00019396   Information provided by National Cancer Institute (NCI)
First Received: March 1, 2007   No Changes Posted
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Stage IV Melanoma
Stage IV Renal Cell Cancer
Recurrent Renal Cell Cancer
Recurrent Melanoma
Additional conditions recognized in this trial
Carcinoma, Renal Cell
Melanoma
Recurrence
More general conditions related to this trial
Adenocarcinoma
Carcinoma
Disease Attributes
Kidney Diseases
Kidney Neoplasms
Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Germ Cell and Embryonal
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Neuroectodermal Tumors
Neuroendocrine Tumors
Nevi and Melanomas
Pathologic Processes
Urogenital Neoplasms
Urologic Diseases
Urologic Neoplasms
Interventions listed in this trial
flt3 ligand
gp100 antigen
MART-1 antigen
Montanide ISA-51
tyrosinase peptide
Additional drug interventions recognized in this trial
Flt3 ligand protein
More general drug interventions related to this trial
Adjuvants, Immunologic
Immunologic Factors
Pharmacologic Actions
Physiological Effects of Drugs
Protective Agents
Radiation-Protective Agents
Sponsors listed in this trial
National Cancer Institute (NCI)


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services